Cramer Rosenthal McGlynn’s Novartis NVS Stock Holding History

Cramer Rosenthal McGlynn’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-405,052	Closed	-$33.4M	–	248
2015 Q3	$33.4M	Sell	405,052 -24,686	-6%	-$2.2M	0.45%	88
2015 Q2	$37.9M	Sell	429,738 -224,824	-34%	-$20.6M	0.47%	97
2015 Q1	$57.8M	Buy	+654,562	New	+$58.1M	0.65%	61

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Institutional Capital Chicago, Illinois $6.75B AUM 3.44% 1-Year Est. Return

Cramer Rosenthal McGlynn's NVS Position: Q4 2015 in Review

Cramer Rosenthal McGlynn sold out of Novartis (NVS) in Q4 2015, closing a stake of 405,052 shares — an estimated $33.4M sold.

Cramer Rosenthal McGlynn first reported a position in NVS in Q1 2015 and held it in 3 quarters. The position peaked at $57.8M in Q1 2015. 926 funds tracked by Wall St. Rank hold NVS as of Q4 2015.

Cramer Rosenthal McGlynn reported no remaining Novartis position as of Q4 2015 after selling out during the quarter.
Cramer Rosenthal McGlynn sold 405,052 Novartis shares in Q4 2015, an estimated $33.4M.
Cramer Rosenthal McGlynn first reported a position in Novartis in Q1 2015 and held it in 3 quarters.
Cramer Rosenthal McGlynn's Novartis position peaked at $57.8M in Q1 2015.
926 funds tracked by Wall St. Rank held Novartis as of Q4 2015.

Based on Cramer Rosenthal McGlynn's 13F filing for Q4 2015, filed 12 Feb 2016.